» Articles » PMID: 30631050

MiR-1254 Inhibits Cell Proliferation, Migration, and Invasion by Down-regulating Smurf1 in Gastric Cancer

Overview
Journal Cell Death Dis
Date 2019 Jan 12
PMID 30631050
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Gastric cancer (GC) is one of the most frequent malignancies, and increasing evidence supports the contribution of microRNA (miRNAs) to cancer progression. miR-1254 has been confirmed to participate in the regulation of various cancers, while the function of miR-1254 in GC remains unknown. In this study, we investigated the role of miR-1254 in GC. The expression of miR-1254 was detected in human GC specimens and cell lines by miRNA RT-PCR. The effects of miR-1254 on GC proliferation were determined by CCK-8 proliferation assays, colony formation assays, 5-ethynyl-2'-deoxyuridine (EdU) incorporation, and cell-cycle assays. The ability of migration and invasion was examined by transwell and wound-healing assay. Dual Luciferase reporter assay was used to validate the interaction of miR-1254 with its target gene. The xenograft mouse models were conducted to investigate the effects of miR-1254 in vivo. The signaling pathways and epithelial-mesenchymal transition (EMT)-related proteins were detected with western blot. The results showed that miR-1254 inhibited the proliferation, migration and invasion in vitro and suppressed tumorigenesis in vivo. Smurf1 was shown to be the direct target of miR-1254. Overexpressing Smurf1 could partially counteract the effects caused by miR-1254. Similarly, the effects of the miR-1254-inhibitor were also rescued by Smurf1-shRNA. Furthermore, we found that miR-1254 inhibited EMT and decreased the PI3K/AKT signaling pathway through downregulating Smurf1. In summary, overexpression of miR-1254 could suppress proliferation, migration, invasion, and EMT via PI3K/AKT signaling pathways by downregulation of Smurf1 in GC, which suggests a potential therapeutic target for GC.

Citing Articles

Has_circ_ASH1L acts as a sponge for miR-1254 to promote the malignant progression of cervical cancer by targeting CD36.

Zhang J, Zhang Y, Li X, Bao Y, Yang J Cancer Gene Ther. 2025; 32(2):214-226.

PMID: 39748122 DOI: 10.1038/s41417-024-00866-5.


The long noncoding RNA ELFN1-AS1 promotes gastric cancer growth and metastasis by interacting with TAOK1 to inhibit the Hippo signaling pathway.

Wang Y, Shen K, Cheng Q, Zhou X, Liu K, Xiao J Cell Death Discov. 2024; 10(1):465.

PMID: 39528458 PMC: 11555383. DOI: 10.1038/s41420-024-02235-5.


Molecular Insight into Gastric Cancer Invasion-Current Status and Future Directions.

Matsuoka T, Yashiro M Cancers (Basel). 2024; 16(1).

PMID: 38201481 PMC: 10778111. DOI: 10.3390/cancers16010054.


Fibroblast activation protein: Pivoting cancer/chemotherapeutic insight towards heart failure.

Gehris J, Ervin C, Hawkins C, Womack S, Churillo A, Doyle J Biochem Pharmacol. 2023; 219:115914.

PMID: 37956895 PMC: 10824141. DOI: 10.1016/j.bcp.2023.115914.


Unraveling the Complex Web of Mechanistic Regulation of Versatile NEDD4 Family by Non-Coding RNAs in Carcinogenesis and Metastasis: From Cell Culture Studies to Animal Models.

Datkhayev U, Rakhmetova V, Shepetov A, Kodasbayev A, Datkayeva G, Pazilov S Cancers (Basel). 2023; 15(15).

PMID: 37568787 PMC: 10417118. DOI: 10.3390/cancers15153971.


References
1.
Narimatsu M, Bose R, Pye M, Zhang L, Miller B, Ching P . Regulation of planar cell polarity by Smurf ubiquitin ligases. Cell. 2009; 137(2):295-307. DOI: 10.1016/j.cell.2009.02.025. View

2.
Brabletz T, Kalluri R, Nieto M, Weinberg R . EMT in cancer. Nat Rev Cancer. 2018; 18(2):128-134. DOI: 10.1038/nrc.2017.118. View

3.
Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

4.
Smith B, Bhowmick N . Role of EMT in Metastasis and Therapy Resistance. J Clin Med. 2016; 5(2). PMC: 4773773. DOI: 10.3390/jcm5020017. View

5.
Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View